Detalhe da pesquisa
1.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
N Engl J Med
; 383(9): 825-835, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846061
2.
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
Oncologist
; 27(1): 22-29, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34523767
3.
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Oncologist
; 27(1): 13-21, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516023
4.
Standard Venipuncture vs a Capillary Blood Collection Device for the Prospective Determination of Abnormal Liver Chemistry.
J Appl Lab Med
; 8(3): 535-550, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533519
5.
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Clin Cancer Res
; 29(16): 2979-2987, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36996322
6.
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
J Thorac Oncol
; 17(6): 768-778, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35183775
7.
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Nat Commun
; 13(1): 1450, 2022 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35304457
8.
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
Clin Cancer Res
; 27(15): 4160-4167, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34088726
9.
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Clin Cancer Res
; 27(1): 34-42, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33082208
10.
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma.
Thyroid
; 30(9): 1384-1389, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292131
11.
Common endothelial progenitor cell assays identify discrete endothelial progenitor cell populations.
Am Heart J
; 157(2): 335-44, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19185643
12.
Emergency Radiology "Boot Camp": Educating Emergency Medicine Residents Using E-learning Radiology Modules.
AEM Educ Train
; 1(1): 43-47, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30051008
13.
Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Nat Commun
; 13(1): 1936, 2022 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383193
14.
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036231
15.
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Clin Lung Cancer
; 22(3): e442-e445, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32660930